<DOC>
	<DOC>NCT02042014</DOC>
	<brief_summary>To provide continued treatment to Pulmonary Arterial Hypertension (PAH) patients who are benefitting from treatment with QTI571.</brief_summary>
	<brief_title>Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>patient is receiving QTI571 for the treatment of Pulmonary Arterial Hypertension (PAH) and is currectly enrolled in a longterm extension study (CQTI571A2301E1) in Japan. Patient is currently benifitting form the treatment with QTI571 in the opinion of the investigator. Patient has been permanently discontinued from QTI571 study treatment in the parent study. Concomitant use of oral vitamin K antagonist medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pulmonary arterial hypertension, QTI571, open label study</keyword>
</DOC>